HomeCompareSHXWF vs PFE

SHXWF vs PFE: Dividend Comparison 2026

SHXWF yields 6.28% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SHXWF wins by $7820.10M in total portfolio value
10 years
SHXWF
SHXWF
● Live price
6.28%
Share price
$1.33
Annual div
$0.08
5Y div CAGR
94.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7820.15M
Annual income
$7,520,671,518.10
Full SHXWF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SHXWF vs PFE

📍 SHXWF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHXWFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHXWF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHXWF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHXWF
Annual income on $10K today (after 15% tax)
$533.65/yr
After 10yr DRIP, annual income (after tax)
$6,392,570,790.39/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SHXWF beats the other by $6,392,548,470.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHXWF + PFE for your $10,000?

SHXWF: 50%PFE: 50%
100% PFE50/50100% SHXWF
Portfolio after 10yr
$3910.10M
Annual income
$3,760,348,888.41/yr
Blended yield
96.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SHXWF
No analyst data
Altman Z
2.3
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHXWF buys
0
PFE buys
0
No recent congressional trades found for SHXWF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHXWFPFE
Forward yield6.28%6.13%
Annual dividend / share$0.08$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR94.8%13.2%
Portfolio after 10y$7820.15M$49.6K
Annual income after 10y$7,520,671,518.10$26,258.71
Total dividends collected$7799.14M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SHXWF vs PFE ($10,000, DRIP)

YearSHXWF PortfolioSHXWF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,923$1,222.99$9,153$693.39+$2.8KSHXWF
2$15,412$2,654.69$8,593$849.25+$6.8KSHXWF
3$22,739$6,247.42$8,336$1,066.78+$14.4KSHXWF
4$41,111$16,780.39$8,437$1,384.80+$32.7KSHXWF
5$99,221$55,232.99$9,013$1,875.40+$90.2KSHXWF
6$348,858$242,691.53$10,306$2,680.72+$338.6KSHXWF
7$1,926,751$1,553,472.80$12,820$4,101.38+$1.91MSHXWF
8$17,681,776$15,620,152.27$17,673$6,826.70+$17.66MSHXWF
9$279,889,545$260,970,044.16$27,543$12,591.86+$279.86MSHXWF
10$7,820,153,331$7,520,671,518.10$49,560$26,258.71+$7820.10MSHXWF

SHXWF vs PFE: Complete Analysis 2026

SHXWFStock

Xinhua Winshare Publishing and Media Co., Ltd., together with its subsidiaries, engages in the publishing and distribution businesses in the People's Republic of China. The company operates in two segments, Publication and Distribution. The Publication segment publishes books, journals, audio-visual products, and digital products; provides printing services; and supplies printing materials. The Distribution segment distributes textbooks and supplementary materials to schools, teachers, and students; and supplies education informatization and equipment services for primary and secondary schools, as well as engages in the retail, distribution, and online sale of publications. The company also sells books, newspapers, journals, artwork, and electronic equipment, as well as electronic publications; produces audio and video tapes; and provides logistics, assets management, education ancillary, and business services. In addition, it is involved in the wholesale and retail of pre-packaged food and dairy products; import and export business; property leasing; catering and ticket agency; and advertising agency and leasing business. Further, the company engages in the wholesale and retail distribution of goods; project investment and management; and organizing and planning of cultural and art exchange activities. Additionally, it offers computer software development and system services; business consulting; travel agency and related services; study tour event planning, conference, and exhibition services. The company was formerly known as Sichuan Xinhua Winshare Chainstore Co., Ltd. and changed its name to Xinhua Winshare Publishing and Media Co., Ltd. in 2010. The company was founded in 2005 and is headquartered in Chengdu, the People's Republic of China. Xinhua Winshare Publishing and Media Co., Ltd. is a subsidiary of Sichuan Xinhua Publishing and Distribution Group Co., Ltd.

Full SHXWF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SHXWF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHXWF vs SCHDSHXWF vs JEPISHXWF vs OSHXWF vs KOSHXWF vs MAINSHXWF vs JNJSHXWF vs MRKSHXWF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.